Paraza Pharma is happy to announce a joint publication with Epics Therapeutics entitled “Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models.” J. Med. Chem. 2025, ASAP.
Paraza Pharma is happy to announce a joint publication with Epics Therapeutics entitled “Discovery, Optimization, and Preclinical Pharmacology of EP652, a METTL3 Inhibitor with Efficacy in Liquid and Solid Tumor Models.” J. Med. Chem. 2025, ASAP.
Canada: +1 514-395-4501
info@parazapharma.com
© Paraza Pharma, Inc. All rights reserved.
Privacy policy